Immunotoxicology of the liver: Adverse reactions to drugs

Journal of Hepatology, Supplement

Volumn 26, Issue 2, 1997, Pages 37-42

  Beaune, Philippe H ^a,b   Lecoeur, Sylvaine ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

Author keywords

Autoantibodies; Covalent binding; Drug; Hepatitis; Immunotoxicology; Liver; Metabolism

Indexed keywords

ANTICONVULSIVE AGENT; AUTOANTIBODY; CARBAMAZEPINE; DIHYDRALAZINE; HALOTHANE; IPRONIAZID; PHENOBARBITAL; PHENYTOIN; TIENILIC ACID;

CONFERENCE PAPER; COVALENT BOND; HEPATITIS; HUMAN; IMMUNE RESPONSE; IMMUNOTOXICITY; LIVER METABOLISM; LIVER TOXICITY; PRIORITY JOURNAL;

EID: 0030964278     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(97)80495-3     Document Type: Conference Paper

References (46)

1. Sherlock S. The spectrum of hepatotoxicity due to drugs. Lancet 1986; ii: 440-1.
2. Mitchell JR, Jollow DJ. Potter WZ, Guette JR, Brodie BB. Acetaminophen-induced hepatic necrosis IV. J Pharmacol ExpTher 1973; 187:211-7.
3. Stricker BHC, ed. Drug-induced Hepatic Injury. Amsterdam: Elsevier, 1992.
4. Trowell J, Peto R, Crampton J, Smith A. Controlled trial of repeated halothane anaesthetics in patients with carcinoma of the uterine cervix treated with radium. Lancet 1975: 8214.
5. Wright R, Eade OE, Chisolm M, Hawksley M, Lloyd B, Moles T.M, Edwards J.C, Gardner M.J. Controlled prospective study of the effect on liver function of multiple exposures to halothane. Lancet 1975; i: 817-20.
6. Zimmerman HJ. Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. New York: Appleton Century Crofts, 1978.
7. Beaune PH, Pessayre D, Dansette P, Mansuy D, Manns M. Autoantibodies against cytochrome P450: role in human diseases. Adv Pharmacol 1994; 30: 199-245.
8. Sipes IG, Gandolfi J, Pohl LR, Krishna G, Brown BR. Comparison of the biotransformation and hepatotoxicity of halothane and deuterated halothane. J Pharmacol Exp Ther 1980; 214: 716-20.
9. Plummer JL, Beckwith ALJ, Bastin FN, Adams JF, Cousins M, Hall P. Free radical formation. In vivo and hepatotoxicity due to anesthesia with halothane. Anesthesiology 1982; 57: 160-6.
10. Satoh H, Fukuda Y, Anderson DK, Ferrans VJ, Gillette JR, Pohl LR. Immunological studies on the mechanism of halothane-induced hepatotoxicity: immunohistochemical evidence of trifluoroacetylated hepatocytes. J Pharmacol Exp Ther 1985; 233: 857-62.
11. Kenna JG, Martin JL, Satoh H, Pohl LR. Factors affecting the expression of trifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane. Drug Metab Dispos 1990; 18: 788-93.
12. Satoh H, Gillette JR, Davies HW, Schulick RD, Pohl LR. Immunochemical evidence of trifluoroacetylated cytochrome P450 in the liver of halothane treated rats. Mol Pharmacol 1985; 28: 468-74.
13. Satoh H, Davies HW, Takemura T, Gillette JR, Maeda K, Pohl LR. An immunochemical appproach to investigating the mechanism of halothane-induced hepatoto.xicity. Prog Drug Metab 1987; 10: 187-205.
14. Satoh H, Martin BM, Schulick AH, Christ DD, Kenna JG, Pohl LR. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. Proc Natl Acad Sci USA 1989; 86: 322-6.
15. Kenna JG, Martin JL, Pohl LR. Purification of trifluoroacetylated protein antigens from livers of halothane-treated rats. Eur J Pharmacol 1990; 183: 1139-40.
16. Kenna JG, Martin JL, Pohl LR. The topography of trifluoroacetylated protein antigens in liver microsomal fractions from halothane treated rats. Biochem Pharmacol 1992; 44: 621-9.
17. Gut J, Christen U, Huwyler J, Bürgin M, Kenna JG. Molecular mimicry of trifluoroacetylated human liver protein adducts by constitutive proteins and immunochemical evidence for its impairment in halothane hepatitis. Eur J Biochem 1992; 210: 569-76.
18. Christen U, Jeno P, Gut J. Halothane metabolism: the dihydrolipoamide acetyltransferase subunit of the pyruvate dehydrogenase complex molecularly mimics trifluoroacetyl-protein adducts. Biochemistry 1993; 32: 1492-9.
19. Kenna JG, Scatchard K, Van Pelt FNAM, Knight TL. Antibodies to halothane-induced liver antigens in sera from patients with halothane hepatitis: evidence for conformationdependent antigen. Br J Clin Pharmacol 1992; 34: 154.
20. Poupon R, Homberg JC, Abuaf N, Petit J, Bodin F, Darnis F. Atteintes hépatiques dues àl'acide ténilique. Six observations avec présence d'anticorps antireticulum endoplasmique. Nouv Presse Med 1980; 9: 1881-4.
21. Zimmerman HJ, Lewis JH, Ishak KG, Maddrey W. Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 1984; 4: 315-23.
22. Colliard M, Homberg JC, Tcherdakoff Ph. Hypertendus traités àl'acide tiénilique. Etude rétrospective de 298 observations. Nouv Presse Med 1981; 10: 2475-8.
23. Homberg JC, André C, Abuaf N. A new anti-liver-kidneymicrosome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol 1984; 55: 561-70.
24. Homberg JC, Abuaf N, Helmy-Khalil S, Biour M, Poupon R, Islam S, Darnis F, Levy VG, Opolon P, Beaugrand M, Toulet J, Danan G, Benhamou JR Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology 1985; 5: 722-7.
25. Mansuy D, Dansette P, Foures C, Jaouen M, Moinet G, Bayer N. Metabolic hydroxylation of the thiophene ring: isolation of 5-hydroxytienilic acid as the major urinary metabolite in rat and man. Biochem Pharmacol 1984; 33: 1429-35.
26. Dansette PM, Amar C, Valadon P, Pons C, Beaune PH, Mansuy D. Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes: catalysis by a P450IIC different from that responsible for mephenytoin hydroxylation. Biochem Pharmacol 1991; 41: 553-60.
27. Lecoeur S, Bonierbale E, Challine D, Gautier JC, Valadon P, Dansette P, Catinot R, Ballet F, Mansuy D, Beaune PH. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity. Chem Res Toxicol 1994; 7: 434-42.
28. Lôpez-Garcia MP, Dansette PM, Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P450: inactivation of yeast expressed human liver cytochrome P450 2C9 by tienilic acid. Biochemistry 1994, in press.
29. Beaune PH, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, Leroux JP, JC. Human anti-endoplasmic reticulum autoantibodies appearing in a drug induced hepatitis are directed against a human liver cytochrome P450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987; 84: 5515.
30. Mansuy D, Valadon P, Erdelmeier I, Lôpez-Garcia MP, Amar C, Girault JP, Dansette PM. Thiophene-S-oxides as new reactive metabolites: formation by cytochrome P450-dependent oxidation and reaction with nucleophiles. J Am Chem Soc 1991; 113:7825-6.
31. Roschlau G, Baumgarten R, Fengler J-D. Die Dihydralazin Hepatitis. Zentralbl Allg Pathol Pathol Anat 1990; 136: 127-34.
32. Machnik G, Bergert A, Justus J, Kunze P, Müller R, Reinhardt M, Schulz H, Stein G, Thiele R. Arzneimittelhepatitis nach Dihydralazin mit tödlichem Verlauf. Zentralbl Allg Pathol Pathol Anat 1988; 134: 167-77.
33. Schneider T, Siegmund W, Zschiesche M, Kallwellis R, Scherber A. Zum qualitativen Nachweis von Metaboliten des Dihydralazins beim Menschen. Pharmazie 1988; 43: 33-6.
34. Schröder LW, Siegmund W, Schneider T, Lohberg T, Grisk A. Zur Blutdruckwirksamkeit ausgewälhter Dihydralazinmetabolite. Pharmazie 1986; 41: 439.
35. Bourdi M, Tinel M, Beaune P, Pessayre D. Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol Pharmacol 1994; 45: 1287-95.
36. Bourdi M, Gautier JC, Mircheva J, Larrey D, Guillouzo A, André C, Belloc C, Beaune Ph. Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: specificity of autoantibodies and inductive capacity of the drug. Mol Pharmacol 1992; 42: 280-5.
37. Bourdi M, Larrey D, Nataf J, Bernuau J, Pessayre D, Iwasaki M, Guengerich FP, Beaune PH. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P450 IA2: a specific marker of dihydralazine-induced hepatitis. J Clin Invest 1990; 85: 1967-73.
38. Leeder JS, Riley RJ, Cook VA, Spielberg P. Human anticytochrome P450 antibodies in aromatic anticonvulsivantsinduced hypersensitivity reactions. J Pharmacol Exp Ther 1992; 263: 360-7.
39. Riley RJ, Smith G, Wolf CR, Cook VA, Leeder JS. Human anti endoplasmic reticulum autoantibodies produced in aromatic anticonvulsivant hypersensitivity reactions recognise rodent CYP 3A proteins and similarly regulated human P450 enzymes (s). Biochem Biophys Res Commun 1993; 191: 3240.
40. Shear H, Spielberg SP. Anticonvulsivant hyper sensitivity syndrome, in vitro assessment of risk. J Clin Invest 1988; 82: 1826-32.
41. Spielberg SP, Gordon GB, Blake GB, Goldstein DA, Herlong HF. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981; 305: 722-7.
42. Vergani D, Mieli-Vergani G, Alberti A, Neuberger J, Eddieston ALVVF, Williams R. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med 1980; 303: 66-71.
43. Paronetto F, Popper H. Lymphocyte stimulation induced by halothane in patients with hepatitis following exposure to halothane. N Engl J Med 1970; 283: 277-80.
44. Kunze KD, Porst H, Tschöpel L. Morphologie und Pathogenese von Leberschäden durch Dihydralazin, Propanolol und Ketophenylbutazon. Zentralbl Allg Pathol Pathol Anat 1985; 130: 509-18.
45. Loeper J, Descatoire V, Maurice M, Beaune P, Belghiti J, Houssin D, Ballet F, Feldmannn G, Guengerich FP, Pessayre D. Cytochromes P450 in human hepatocyte plasma membrane: recognition by several autoantibodies. Gastroenterology 1993; 104: 203-16.
46. Loeper J, Descatoire V, Maurice M, Beaune P, Feldmann G, Larrey D, Pessayre D. Presence of functional cytochrome P450 on isolated rat hepatocyte plasma membrane. Hepatology 1990; 1: 850-8.